JAZZ PHARMACEUTICALS PLC shareholders Q3 2023

JAZZ PHARMACEUTICALS PLC's ticker is JAZZ and the CUSIP is G50871105. A total of 476 filers reported holding JAZZ PHARMACEUTICALS PLC in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.

JAZZ PHARMACEUTICALS PLC shareholders Q3 2023
Name	Shares	Value	Weighting ↓
NEW YORK STATE COMMON RETIREMENT FUND	109,586	$14,185	0.02%
Allspring Global Investments Holdings, LLC	87,781	$11,362,372	0.02%
CANADA PENSION PLAN INVESTMENT BOARD	104,600	$13,539,424	0.02%
JPMORGAN CHASE & CO	1,426,041	$184,586,813	0.02%
Treasurer of the State of North Carolina	28,447	$3,682	0.02%
VANGUARD GROUP INC	6,379,053	$825,704,620	0.02%
SIT INVESTMENT ASSOCIATES INC	5,700	$738	0.02%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	101,607	$13,152,010	0.02%
Tredje AP-fonden	10,591	$1,370,899	0.02%
Centiva Capital, LP	6,993	$905,174	0.02%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	119,101	$15,416	0.02%
VICTORY CAPITAL MANAGEMENT INC	130,975	$16,953,404	0.02%
BALYASNY ASSET MANAGEMENT L.P.	70,922	$9,180,144	0.02%
Teza Capital Management LLC	1,561	$202,056	0.02%
XPONANCE, INC.	10,948	$1,417,109	0.02%
Utah Retirement Systems	10,436	$1,350,836	0.02%
Arizona State Retirement System	17,498	$2,264,941	0.02%
State of Tennessee, Treasury Department	36,780	$4,760,804	0.02%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	513,978	$66,529,313	0.02%
Legal & General Group Plc	411,348	$53,244,885	0.02%

About JAZZ PHARMACEUTICALS PLC

Jazz Pharmaceuticals plc is a biopharmaceutical company that specializes in developing and commercializing medicines for patients with serious medical conditions. The company's portfolio includes products for the treatment of sleep disorders, oncology, and hematology.

One of Jazz Pharmaceuticals' most successful products is Xyrem, a medication used to treat narcolepsy. Xyrem has been approved by the FDA since 2002 and has been a significant revenue generator for the company. In addition to Xyrem, Jazz Pharmaceuticals has a number of other products in its pipeline, including treatments for Parkinson's disease and epilepsy.

Jazz Pharmaceuticals has a strong leadership team, including CEO Bruce Cozadd and COO Daniel Swisher. The company has a market capitalization of over $8 billion and has consistently delivered strong financial results. In 2020, Jazz Pharmaceuticals reported revenue of $2.3 billion, an increase of 10% compared to the previous year.

Despite the challenges posed by the COVID-19 pandemic, Jazz Pharmaceuticals has continued to invest in research and development. The company recently announced positive results from a Phase 3 clinical trial of its treatment for acute lymphoblastic leukemia, which could potentially become a significant revenue driver in the future.

Overall, Jazz Pharmaceuticals is a well-respected company in the biopharmaceutical industry with a strong track record of success. With a robust pipeline of products and a talented leadership team, the company is well-positioned for continued growth in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists JAZZ PHARMACEUTICALS PLC's shareholders in Q3 2023. To view JAZZ PHARMACEUTICALS PLC's shareholder history, click here.